The bowel refers to the lowermost portion of the gastrointestinal (GI) tract. Structural or biochemical abnormalities associated with the bowel can give rise to a variety of disorders, with common examples including ulcerative colitis and Crohn’s disease, collectively termed inflammatory bowel disease. In the case of ulcerative colitis, there is chronic inflammation of the colon and rectum. Meanwhile in Crohn’s disease, though inflammation may occur anywhere along the gut, it most frequently manifests in the ileum.
Recurrent or persistent abdominal pain, diarrhoea, fatigue and loss of appetite are some of the symptoms most frequently reported by patients with bowel disorders. Treatment of bowel disorders can prove challenging; however alleviation of symptoms may be achieved through dietary alterations or pharmacological interventions.
To find out more about the diagnosis and treatment of some of the most common bowel disorders, visit our dedicated “Anti-integrins in IBD” and “Inflammatory bowel disease assessment tools” Learning Zones, with a disease overview available in our Inflammatory Bowel Disease Knowledge Centre.
Featured Learning Zones
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Anti-integrins in IBD Learning Zone
The growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has provided a variety of novel therapeutic targets. Apart from the tumour necrosis factor-α mediated pathway, which is the target of the first marketed biologics in this indication, several other pathways are involved in triggering an inflammatory response.
Inflammatory Bowel Disease
Treatment options for inflammatory bowel disease (IBD) are evolving as knowledge of the condition is increasing. In the future, physicians may be able to offer therapy tailored to individual patients. This Learning Zone describes the background behind such advances.
Related news and insights
akeda Pharmaceutical Company Limited announced interim results from the VISIBLE open-label extension (OLE) study on the long-term safety and efficacy of maintenance treatment with the subcutaneous (SC) formulation of the gut-selective biologic Entyvio (vedolizumab) in patients with moderately to severely active ulcerative colitis (UC) .
Gilead Sciences, Inc. and Galapagos NV presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis (UC) .
Bristol Myers Squibb announced detailed results from True North, a pivotal, placebo-controlled Phase III trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for patients with moderate to severe ulcerative colitis. (UC).
The guideline has been condensed into two papers,[...] the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].
The goal of this consensus initiated by the European Crohn’s and Colitis Organisation [ECCO] and European Society of Colo-Proctology [ESCP] was to establish European consensus guidelines for the surgical treatment of Crohn’s disease [CD].
You may be interested in...
The Union-North America Region (NAR) is the regional arm of the International Union against Tuberculosis and Lung Disease (The Union), a global public health organization with the vision to provide health solutions to the poor.
28th Conference On Retrovirus And Opportunistic Infections 2021
CROI is the preeminent meeting in the world and attracts more than 4,000 research leaders from nearly 90 countries and nearly half of CROI attendees come from outside the United States. In recent years, more than 1000 abstracts have been selected for presentation at CROI.